Filtered By:
Condition: Diabetes
Drug: Beta-Blockers
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 158 results found since Jan 2013.
More Young Women Are Having Heart Attacks, Study Says. This Could Be Why
Younger women are having more heart attacks, and accounted for nearly a third of all female heart attack patients in recent years, according to a recent study. The news compounds a string of recent findings that have pointed to poorer overall health for young American women.
“Women now, compared to younger women generations before them, are less healthy,” says study co-author Melissa Caughey, a cardiovascular epidemiologist and instructor at the University of North Carolina Chapel Hill School of Medicine. “It’s probably reflective of poorer health in general.”
The study, which appeared in a sp...
Source: TIME: Health - February 21, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime onetime Research Source Type: news
First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
CONCLUSIONS: All-cause death is similar for first-line RAS inhibitors and first-line CCBs, thiazides and beta-blockers. There are, however, differences for some morbidity outcomes. First-line thiazides caused less HF and stroke than first-line RAS inhibitors. First-line CCBs increased HF but decreased stroke compared to first-line RAS inhibitors. The magnitude of the increase in HF exceeded the decrease in stroke. Low-quality evidence suggests that first-line RAS inhibitors reduced stroke and total CV events compared to first-line beta-blockers. The small differences in effect on blood pressure between the different classe...
Source: Cochrane Database of Systematic Reviews - November 14, 2018 Category: General Medicine Authors: Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q, Xue H, Wright JM Tags: Cochrane Database Syst Rev Source Type: research
Secondary CV Prevention in South America in a Community Setting: The PURE Study
ConclusionsThere are large gaps in the use of proven medications for secondary prevention of cardiovascular disease in South America. Strategies to improve the sustained use of these medications will likely reduce cardiovascular disease burden substantially.
Source: Global Heart - July 10, 2018 Category: Cardiology Source Type: research
The Association Between Inflammatory Markers and Hypertension. A Call for Anti-Inflammatory Strategies?
Authors: García NH, Juncos LI
Abstract
The most important goal of antihypertensive therapy is to prevent the complications associated with hypertension (stroke, myocardial infarction, end-stage renal disease, etc). For this, secondary targets such as left ventricular hypertrophy, proteinuria, dementia, and other signs of hypertension-induced organ damage help the physician to assess risks and monitor treatment efficacy. New treatment targets may be arising, however. One such target may be endothelial dysfunction. In effect, endothelial dysfunction not only may precede the elevation of blood pressure, but may also ...
Source: The Scientific World Journal - June 7, 2018 Category: Science Tags: ScientificWorldJournal Source Type: research
Drug Use for Secondary Prevention of Cardiovascular Diseases in Golestan, Iran: Results From the Golestan Cohort Study.
CONCLUSION: Drug use after IHD or stroke is low in Northeast of Iran. Comprehensive efforts to promote secondary prevention are urgently needed.
PMID: 29688733 [PubMed - in process]
Source: Archives of Iranian Medicine - March 1, 2018 Category: Middle East Health Authors: Nalini M, Sepanlou SG, Pourshams A, Poustchi H, Sharafkhah M, Bahrami H, Kamangar F, Malekzadeh R Tags: Arch Iran Med Source Type: research
A New Form of This Miracle Nutrient Is 8 Times More Powerful …
CoQ10 has made the mainstream. You can find it everywhere.
But the type of CoQ10 I want to tell you about has been completely ignored.
That’s too bad, because this new form is 8 times better at getting into your blood and staying there. And that’s where it has its miracle-like anti-aging effects.
This new form of CoQ10 may give you the opportunity to live disease-free for the rest of your life.
Today, I’ll show you how this new “reduced” form of CoQ10 gives you greater power to prevent and reverse disease. You’ll also discover that it ramps up your energy levels and slows your aging process down by a remarkable...
Source: Al Sears, MD Natural Remedies - January 3, 2018 Category: Complementary Medicine Authors: Francisco Cabrera Tags: Nutrition antioxidants CoQ10 ubiquinol Source Type: news
“Quackery” that saves lives
I’m used to being a target of mainstream medicine. I can’t even count the number of times I’ve been called a “quack.”
Let me give you just one example…
For decades I’ve been treating my patients with a proven therapy. The FDA approved it way back in 1953. I use it to help my patients detox from mercury, lead, cadmium and other heavy metals. In fact, more than 100,000 people get this therapy every year in the U.S.
But mainstream doctors still laugh at the idea of this treatment and think it’s pure bunk.
I’m talking about intravenous (IV) chelation.
Even though I’ve...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Randall Hall Tags: Anti-Aging Health Heart Health Men's Health Women's Health Source Type: news
Management and clinical outcome of stable coronary artery disease in Austria : Results from 5 years of the CLARIFY registry.
CONCLUSION: Characteristics of Austrian outpatients with stable CAD corresponded to those of patients with CAD in other developed countries. Medical treatments following the recommendations of the European guidelines were prescribed in the majority of patients; however, recommended goals of life style interventions including a heart rate less than 60 bpm and general risk factor management were not achieved by a high proportion of patients. Heart rate control and life style changes remain unmet needs of cardiovascular care in Austria.
PMID: 28913755 [PubMed - as supplied by publisher]
Source: Wiener Klinische Wochenschrift - September 14, 2017 Category: General Medicine Authors: Lang IM, Badr-Eslam R, Greenlaw N, Young R, Steg PG Tags: Wien Klin Wochenschr Source Type: research
Beta-blockers 'useless' for many heart attack patients, study reports
Conclusion
This study aimed to see whether beta blockers reduce mortality in people who've had a heart attack but who don't have heart failure or systolic dysfunction. It found no difference between those who were and those who were not given beta-blockers on discharge from hospital.
The authors say this adds to the evidence that routine prescription of beta blockers might not be needed for patients without heart failure following a heart attack.
Current UK guidelines recommend all people who have had a heart attack take beta blockers for at least one year to reduce risk of recurrent events. Only people with heart failure ...
Source: NHS News Feed - May 30, 2017 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news
Blood pressure control in anticoagulated patients with hypertension and atrial fibrillation.
CONCLUSIONS: More than 75% of hypertensive patients with AF achieved BP goals, and this rate was higher in elderly. More than 2 thirds of patients were on combined therapy. BP control appears to be better in AF patients than in general hypertensive population.
PMID: 28385080 [PubMed - as supplied by publisher]
Source: Blood Pressure - April 8, 2017 Category: Hematology Tags: Blood Press Source Type: research
Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus non-cardiologists: the international prospective CLARIFY registry.
CONCLUSIONS Outpatients with SCAD managed by cardiologists had a lower rate of cardiovascular outcomes than those managed by non-cardiologists. We did not find clear evidence that cardiologists provided superior guideline-based treatment, so the differences in outcome were most likely due to unquantifiable differences in patient characteristics.
PMID: 28224974 [PubMed - as supplied by publisher]
Source: Polskie Archiwum Medycyny Wewnetrznej - February 24, 2017 Category: Internal Medicine Tags: Pol Arch Med Wewn Source Type: research
Beta-Blocker Use Is Associated With Impaired Left Atrial Function in Hypertension Hypertension
BackgroundImpaired left atrial (LA) mechanical function is present in hypertension and likely contributes to various complications, including atrial arrhythmias, stroke, and heart failure. Various antihypertensive drug classes exert differential effects on central hemodynamics and left ventricular function. However, little is known about their effects on LA function.Methods and ResultsWe studied 212 subjects with hypertension and without heart failure or atrial fibrillation. LA strain was measured from cine steady‐state free‐precession cardiac MRI images using feature‐tracking algorithms. In multivariable models adju...
Source: JAHA:Journal of the American Heart Association - February 3, 2017 Category: Cardiology Authors: Sardana, M., Syed, A. A., Hashmath, Z., Phan, T. S., Koppula, M. R., Kewan, U., Ahmed, Z., Chandamuri, R., Varakantam, S., Shah, E., Gorz, R., Akers, S. R., Chirinos, J. A. Tags: Atrial Fibrillation, Hypertension, Magnetic Resonance Imaging (MRI) Original Research Source Type: research
Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: an overview of systematic reviews
Conclusion: The available evidence supports treatment in people with type 2 diabetes and SBP more than 140 mmHg, using any of the major antihypertensive drug classes.
Source: Journal of Hypertension - January 31, 2017 Category: Cardiology Tags: Reviews Source Type: research
The Role of Beta-Blockers in the Treatment of Hypertension.
CONCLUSIONS AND RELEVANCE: Primary/essential hypertension in younger/middle-age is underpinned by high sympathetic nerve activity. In this age-group high resting heart rates and high plasma norepinephrine levels (independent of blood pressure) are linked to premature cardiovascular events and death. Thus, anti-hypertensive agents that increase sympathetic nerve activity ie diuretics, dihydropyridine calcium blockers, and ARBs, are inappropriate first-line choices in this younger age-group. Beta-blockers perform well vs randomised placebo and other antihypertensive agents regarding reduced risk of death/stroke/myocardial in...
Source: Advances in Experimental Medicine and Biology - December 14, 2016 Category: Research Tags: Adv Exp Med Biol Source Type: research
